Among the many topics covered in detail in our comprehensive Q222 Extremities Market Recap* are:

John Uribe, MD, discusses inset glenoid technology and the future of shoulder replacement

John Uribe, MD, discusses his most recent research and experience with inset glenoids and how inset glenoids could influence the practice of shoulder replacement surgery. Dr. Uribe is a dual board-certified orthopedic surgeon with Baptist Health Group South Florida specializing in sports medicine, arthroscopic surgery and minimally invasive surgical procedures for degenerative knee, shoulder and elbow conditions. He is also the Chair of the Herbert Wertheim College of Medicine, Coral Gables, FL and the team physician for the Florida Panthers hockey team and the Miami Dolphins football team.

Dr. Uribe authored a study published in JSES International reporting results from 39 patients with advanced shoulder arthritis having anatomic shoulder replacement with the OVOMotion Shoulder Arthroplasty System from Anika, a stemless shoulder with an inlay glenoid component. The study demonstrated that treatment with inlay total shoulder arthroplasty resulted in significant functional improvement, pain relief and patient satisfaction at a mean follow-up of 41 months.

To find out more, including Dr. Uribe’s thoughts on the benefits of inlay glenoids vs onlay; the potential acceptance of inlay technology; trends such as the shift to reverse shoulders, site-of-care; and what’s next, click on the video below to listen to the recorded interview (17:36 min). A link to download a complete transcript of the interview is also provided below.

Despite stronger headwinds from slowing elective procedures, supply chain challenges and unfavorable foreign exchange rates, most total joint companies saw positive growth in Q222.

The WW Total Joints Market grew in Q222 despite slowing sequential growth compared to Q122’s growth. A slowdown in elective procedures late in the quarter along with continued supply chain challenges and the effect of foreign exchange rates resulted in stronger headwinds. SmartTRAK notes that several companies reported the carryover of these headwinds into Q3 that could dampen market recovery through year-end.

Among the many topics covered in detail in our comprehensive Q222 Total Joints Market Recap* are:

Michael Chen, MD, the 2022 President of the Society of Neurointerventional Surgery (SNIS) and a neurointerventionalist at Rush University Medical Center in Chicago, discusses advances in stroke care research and innovation in an interview with   SmartTRAK at the SNIS 19 ^th Annual meeting held in Toronto, Ontario, Canada July 25-29, 2022. 

Surgical matrices revenue is flat while procedure volumes level out

With elective procedures in the United States mostly back at pre-pandemic levels, the US Surgical Matrices Market returned to what had been normal growth according to SmartTRAK Financial Dashboard. Becton Dickinson* (BD) grew to a 26.9% share, while AbbVie* slipped to second place.

Among the many topics covered in detail in our comprehensive Q222 US Surgical Matrices Market Recap* are:

The first half of 2022 has delivered both positive and negative developments for the Computer-Assisted Surgery industry. Supply chain issues and surges of COVID-19 infections have continued to have significant impacts on revenues. At the same time, enabling tech product launches proceed at a rapid pace, with some robotic procedures accelerating. The following is a sample of recent CAS news and developments from around the world, compiled by the expert analysts at SmartTRAK.

We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, new products, patents, financial data and competitor developments in the global Life Sciences industry. If you'd like to receive these expert insights daily, Contact Us to learn more.

New Products:

• Globus*
  

  GMED announced completion of the first clinical cases using Excelsius3D w/ the ExcelsiusGPS platform. The surgeries were completed at MedStar Union Memorial Hospital in MD, Northwest Specialty Hospital in ID & NYU Langone Health in NY.

• SeaSpine*

  SPNE touted the Q122 limited commercial launch of FLASH Navigation Lumbar Facet Fusion, which facilitates delivery of OsteoStrand Plus DBM Fiber pellets in spine MIS procedures. It is SPNE’s first procedural solution w/ integrated 7D technology. SPNE Q122 Earnings Press Release

SmartTRAK looks at trends in the Diagnostic Aids market for 2022 with an eye on hard-to-heal wounds, regulatory and reimbursement checkpoints and investment deals and financing.

SmartTRAK  sees continued growth in the Diagnostic Aids market driven by the following factors:

• Hard-to-heal wounds continue to drive resource utilization and cost
• Clinicians need diagnostic tools to help guide more efficient and effective product selection
• Companies are making incremental progress navigating regulatory and reimbursement checkpoints
• Investors see potential value as evidenced by deals and financing

In 2007, the World Union of Wound Healing Societies (WUWHS) published a consensus document on the Principles of Best Practice in Diagnostics and Wounds. The authors identified the need for new diagnostic tests to help identify why some wounds do not respond to advanced therapies. The document further suggested that the ideal diagnostic tool can detect and quantify biomarkers that impact wound healing, such as molecules, biofilms, oxygen content and temperature changes. SmartTRAK looks at trends in the Diagnostic Aids market in 2022 with a focus on ...

To download and read the complete article "Wound Care Diagnostic Aids: Trends to Watch in 2022 and Beyond" just click the button below.

Q122 proved to be a mixed-bag of ups and downs with supply chain issues and Covid surges having varying impacts on market leaders’ performance amidst a strong wave of enabling tech product launches.

The Q122 WW CAS Ortho Market was down according to SmartTRAK Financial Dashboard. Stryker* remained the market leader, followed by Zimmer Biomet* and Smith & Nephew*. For detailed Q122 revenues and shares by company in the US, EU and ROW, see the SmartTRAK CAS Ortho Financial Dashboard.

Among the many topics covered in detail in our comprehensive Q122 CAS Ortho Market Recap* are:

Mr J. David Owens, President & CEO of BiologicsMD, and Chief Scientific Officer, Dr. Robyn Goforth, discuss the Company’s highly-targeted therapies, a series of recombinant fusion proteins designed to treat hair loss and severe bone disorders, in an interview with SmartTRAK.

In an interview with SmartTRAK, BiologicsMD President & CEO J. David Owens and CSO Dr. Robyn Goforth discuss BiologicsMD’s innovative highly-targeted treatments for severe bone disorders and hair loss diseases.

To find out more about this early-stage company, the science behind highly-targeted therapies, and two of its lead compounds, click on the following video to listen to the full interview (29:10 min). A link to download a complete transcript of the interview is also provided below.